Processa Pharmaceuticals (PCSA) PT Lowered to $3 at Oppenheimer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts PCSA Hot Sheet
Price: $1.94 --0%
Rating Summary:
4 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 16 | New: 11
Rating Summary:
4 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 16 | New: 11
Join SI Premium – FREE
Oppenheimer analyst Francois Brisebois lowered the price target on Processa Pharmaceuticals (NASDAQ: PCSA) to $3.00 (from $5.00) while maintaining a Outperform rating.
You May Also Be Interested In
- XPLR Infrastructure (XIFR) PT Lowered to $10 at Scotiabank
- Booking Holdings (BKNG) PT Lowered to $200 at Morgan Stanley
- AMD (AMD) PT Raised to $650 at Melius
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
